AstraZeneca PLC
OTC:AZNCF

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
OTC:AZNCF
Watchlist
Price: 187.8 USD -0.14% Market Closed
Market Cap: $291.1B

Net Margin

21.8%
Current
Improving
by 5.2%
vs 3-y average of 16.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
21.8%
=
Net Income
$9.4B
/
Revenue
$58.1B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
21.8%
=
Net Income
$9.4B
/
Revenue
$58.1B

Peer Comparison

Country Company Market Cap Net
Margin
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.5B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.7B EUR
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
112.1B USD
Loading...
UK
GSK plc
XETRA:GS71
86.1B EUR
Loading...
DE
Bayer AG
XETRA:BAYN
43.2B EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
972.2B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.7B CHF
Loading...
CH
Novartis AG
SIX:NOVN
219.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
272.1B USD
Loading...

Market Distribution

Higher than 99% of companies in United Kingdom
Percentile
99th
Based on 3 670 companies
99th percentile
21.8%
Low
-188 120% — 0%
Typical Range
0% — 0.1%
High
0.1% — 10 443.9%
Distribution Statistics
United Kingdom
Min -188 120%
30th Percentile 0%
Median 0%
70th Percentile 0.1%
Max 10 443.9%

AstraZeneca PLC
Glance View

AstraZeneca PLC stands as a formidable entity in the global pharmaceutical landscape, adeptly navigating the intricate dance of innovation and commerce. Emerging from a merger between Sweden's Astra AB and the UK's Zeneca Group in 1999, the company has carved a niche through its relentless pursuit of cutting-edge medical solutions. Central to its operations is a sophisticated ecosystem of research and development, where thousands of scientists tirelessly explore the expansive frontier of biotechnology. The lifeblood of AstraZeneca's growth is its robust pipeline, where potential life-saving medicines traverse an arduous journey from laboratory benches to clinical trials, and eventually, regulatory approval. This rigorous process underscores its commitment to addressing complex diseases in areas such as oncology, cardiovascular, and respiratory health – domains marked by high unmet medical needs and significant market demand. The commercial prowess of AstraZeneca is equally vital to its success narrative. With a global reach spanning over 100 countries, the company leverages its advanced production facilities and strategic partnerships to deliver its pharmaceutical breakthroughs to those in need. Revenue generation is predominantly through the sale of prescription drugs, with blockbuster medications serving as pivotal financial pillars. These products, once approved, are strategically marketed to healthcare providers, ensuring they gain traction in various markets. AstraZeneca's approach is finely tuned to balance the scale of mass production with the nuance of catering to specific regional demands, maintaining a competitive edge in a crowded pharmaceutical landscape. Through these intricacies of innovation, production, and strategic market positioning, AstraZeneca not only generates substantial revenues but also reinforces its mission to improve patient health outcomes worldwide.

AZNCF Intrinsic Value
209.34 USD
Undervaluation 10%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
21.8%
=
Net Income
$9.4B
/
Revenue
$58.1B
What is AstraZeneca PLC's current Net Margin?

The current Net Margin for AstraZeneca PLC is 21.8%, which is above its 3-year median of 16.6%.

How has Net Margin changed over time?

Over the last 3 years, AstraZeneca PLC’s Net Margin has increased from 5% to 21.8%. During this period, it reached a low of 5% on Sep 30, 2022 and a high of 21.7% on Sep 30, 2025.

Back to Top